1. Cephalon
1.1 Business Overview
1.2 Cephalon Cancer Pipeline Overview

2. Cephalon Cancer Drug in Research Phase
2.1 Anticancer Antibody - Arana Therapeutics

3. Cephalon Cancer Drug in Preclinical Phase
3.1 kinase Inhibitors - Daiichi Sankyo/Teva
3.2 BIL 06v
3.3 Anticancer Therapeutics and Diagnostics - Biosceptre International
3.4 Monoclonal Antibody Therapeutics - AVEO
3.5 CEP 37251
3.6 VEGF Inhibitors - Circadian Technologies
3.7 CXS 273

4. Cephalon Cancer Drug in Clinical Phase
4.1 CEP 8983

5. Cephalon Cancer Drug in Phase-I
5.1 RXDX 105
5.2 BIL 010t
5.3 CEP 37440
5.4 Delanzomib

6. Marketed Cancer Drugs by Cephalon
6.1 Bortezomib (Velcade)
6.2 Doxorubicin Liposomal (Myocet)
6.3 Omacetaxine Mepesuccinate (Synribo)

7. No Development Reported in Cancer Drugs in Clinical Pipeline
7.1 Cytokine-Antibody Conjugated Cancer Therapeutics - Teva
7.2 CXS 6001
7.3 Telomere Capping Inhibitors - Gemin X
7.4 CEP 751
7.5 CEP 1612
7.6 Cancer Therapeutics - Celator/Cephalon
7.7 Antibody Therapeutics - Arana Therapeutics/XOMA
7.8 Apoptosis Inducers - Gemin X

8. Discontinued in Cancer Drugs in Clinical Pipeline
8.1 Obatoclax
8.2 Amonafide
8.3 CEP 7055
8.4 CEP 11981
8.5 RXDX 107
8.6 CEP 2563
8.7 CEP 5214
8.8 Anti-Ganglioside Antibody - Arana
8.9 Hepatocellular Carcinoma Therapy - Arana Therapeutics
8.10 Anticancer Antibodies - EvoGenix/Viventia Biotech
8.11 CXS 4001
8.12 CXS 876
8.13 PTL 03001
8.14 E4orf4 Cancer Gene Therapy - Gemin X
8.15 Protein Kinase Inhibitors - Cephalon/Johnson & Johnson
8.16 Cancer Therapy - Gemin X/Phytera
8.17 Monoclonal Antibody 32
8.18 Anticancer Antibodies - Arana Therapeutics/NIH

9. Suspended in Cancer Drugs in Clinical Pipeline
9.1 CEP 9722
9.2 CXS 299


List of Figures

Figure 1-1: Cephalon Cancer Clinical Pipeline by Phase (%)
Figure 1-2: Cephalon Cancer Clinical Pipeline by Phase (Number)
Figure 1-3: Cephalon Cancer Clinical Pipeline by Phase (%)
Figure 1-4: Cephalon Cancer Clinical Pipeline by Phase (Number)